News and Comments

THE SELECTION, ADVICE, HISTORY, PREFERENCES WILL BE ALL IN THE NEW YEAR'S PROHOST LETTER

  Friday, December 28, 2012

 More...

ARIAD: ICLUSIG'S APPROVAL DESERVES HONORING THE DEVELOPER, NOT BASHING ITS STOCK

  Monday, December 17, 2012

On Friday, December 14, the FDA granted early and accelerated approval of Ariad’s (ARIA) further reaching tyrosine kinase inhibitor Iclusig (ponatinib) for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy. More...

ImmunoGen's Press Release Is More Than Mere News

  Tuesday, December 04, 2012

Give me the money or the hope of having it; you will see what I can do with my Targeted Antibody Payload (TAP) technology and my proprietary antibodies. That’s the message we feel ImmunoGen (IMGN) has meant to send about its upcoming clinical data presentations at the 54th annual meeting of the American Society of Hematology (ASH) to be held December 8-11, 2012 in Atlanta, GA. More...

THE ROAD TOWARDS FAR-REACHING THERAPEUTICS THROUGH ILMN, SRPT AND EXEL.

  Monday, December 03, 2012

ILLUMINA (ILMN): Illumina is approaching its 52week high. We remind that around June/July 2011  the stock had reached for over $75 to be badly hit because of fear of the bad economy and dwarfing of the healthcare budget, which was relevant. The stock had reached as low as the mid-twenties. At the time we believed this price was an invitation to buy the stock. As a matter of fact ILMN  jumped overnight from around $30 to over $50 following Roche’s offer to buy the firm.       More...


Recent News_and_Comments


Archive


Tags